---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-171157"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2023-06-21T23:59:59+00:00"
generated_at: "2026-06-13T20:09:42.172627+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# AlloVir suspends ATM equity program; terminates prospectus supplement with SVB

## Summary
- Notified SVB Securities on June 21, 2023 to suspend and terminate the ATM prospectus supplement.
- No sales of common stock will be made under the Sales Agreement until a new prospectus supplement or registration statement is filed.
- Sales Agreement dated August 6, 2021 remains in full force and effect except for the terminated supplement.

## SEC filing metadata
- accession: 0001193125-23-171157
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2023-06-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312523171157/0001193125-23-171157-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312523171157/d462085d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-171157
- JSON: https://secwatch.observer/filing/0001193125-23-171157.json
- Plain text: https://secwatch.observer/filing/0001193125-23-171157.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.